Ganglioside

Gangliosides are a specialized class of sialic acid-containing glycosphingolipids primarily located on the outer leaflet of cell plasma membranes, where they are particularly abundant in the nervous system [9, 12]. They serve as critical components of lipid rafts, orchestrating essential biological processes such as signal transduction, cell-cell recognition, and adhesion by modulating the activity of various transmembrane proteins and growth factor receptors [1, 11]. In oncology, specific gangliosides like GD2 and GD3 are frequently overexpressed in neuroectoderm-derived tumors, making them valuable targets for immunotherapies such as monoclonal antibodies and CAR-T cells [4, 14]. Beyond their role as cancer antigens, gangliosides are implicated in the pathogenesis of neurodegenerative disorders like Parkinson's disease and are the primary accumulating substrates in lysosomal storage diseases such as Tay-Sachs [12, 16]. Therapeutic strategies targeting gangliosides often focus on immune-mediated cell destruction or blocking viral entry, though the expression of these molecules on normal nerve fibers can lead to significant clinical challenges like severe neuropathic pain [14, 15].

Other names

Sialylated glycosphingolipidsAcidic glycosphingolipidsSialic acid-containing glycosphingolipidsSialoglycans

Drugs targeting gangliosides primarily utilize monoclonal antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells overexpressing these antigens [8, 14]. Other mechanisms include the inhibition of oncogenic signal transduction through the disruption of lipid raft-associated receptors and the replenishment of deficient gangliosides to provide neuroprotection in degenerative states [5, 16].